https://www.activebiotech.com/en/presentation/laquinimod-treatment-of-inflammatory-eye-disorders/2020-11-24T15:28:31+01:00https://www.activebiotech.com/en/presentation/laquinimod-treatment-of-inflammatory-eye-disorders-pdf/2020-11-24T15:20:54+01:00https://www.activebiotech.com/en/presentation/tasquinimod-treatment-of-multiple-myeloma/2020-11-24T15:10:49+01:00https://www.activebiotech.com/en/presentation/tasquinimod-treatment-of-multiple-myeloma-pdf/2020-11-24T15:09:44+01:00https://www.activebiotech.com/en/presentation/an-introduction-to-multiple-myeloma/2020-11-24T15:07:26+01:00https://www.activebiotech.com/en/presentation/an-introduction-to-multiple-myeloma-pdf/2020-11-24T15:06:04+01:00https://www.activebiotech.com/en/presentation/a-phase-1-study-of-tasquinimod-in-patients-with-relapsed-or-refractory-multiple-myeloma/2020-11-24T15:05:21+01:00https://www.activebiotech.com/en/presentation/a-phase-1-study-of-tasquinimod-in-patients-with-relapsed-or-refractory-multiple-myeloma-pdf/2020-11-24T15:04:06+01:00https://www.activebiotech.com/en/presentation/naptumomab-next-generation-immunotherapy-capable-of-targeting-cold-tumors/2020-11-24T15:03:05+01:00https://www.activebiotech.com/en/presentation/naptumomab-next-generation-immunotherapy-capable-of-targeting-cold-tumors-pdf/2020-11-24T15:02:49+01:00https://www.activebiotech.com/en/presentation/active-biotechs-presentation-at-solebury-trout-european-biotech-investor-days-2021/2021-05-02T16:07:51+02:00https://www.activebiotech.com/en/presentation/active-biotechs-presentation-at-aktiedagen-may-4-2021-swedish-shareholders-association-in-swedish/2021-05-04T16:09:06+02:00https://www.activebiotech.com/en/presentation/capital-markets-day-2020/2020-11-24T15:00:47+01:00https://www.activebiotech.com/en/presentation/abgsc-life-science-summit-25-maj-2021/2021-05-28T11:17:02+02:00https://www.activebiotech.com/en/presentation/active-biotech-vd-helen-tuvesson-presenterar-vid-redeye-life-science-day-2020-2/2020-12-01T15:37:04+01:00https://www.activebiotech.com/en/presentation/active-biotech-ceo-helen-tuvesson-presents-at-redeye-growth-day-2021-swedish/2021-06-07T14:14:48+02:00https://www.activebiotech.com/en/presentation/active-biotech-will-present-at-aktiespararnas-aktiedag-lund-in-swedish/2021-09-28T15:04:14+02:00https://www.activebiotech.com/en/presentation/active-biotechs-presentation-at-aktiespararnas-aktiedagen-lund-january-31-2022/2022-01-31T16:54:18+01:00https://www.activebiotech.com/en/presentation/active-biotech-in-focus-interview-with-helen-tuvesson-ceo-at-redeye-growth-day-2022/2022-06-10T09:22:50+02:00https://www.activebiotech.com/en/presentation/active-biotech-redeye-interview-with-ceo-helen-tuvesson-in-swedish/2022-08-22T10:10:34+02:00https://www.activebiotech.com/en/presentation/active-biotech-to-present-on-aktiespararnas-aktiedagen-lund-september-26-2022-in-swedish/2022-09-27T09:21:15+02:00https://www.activebiotech.com/en/presentation/hur-bygger-man-ett-lo%cc%88nsamt-life-science-bolag-aktiedagen-january-27-2021-in-swedish/2021-01-27T16:18:24+01:00https://www.activebiotech.com/en/presentation/active-biotech-infocus-interview-with-ceo-helen-tuvesson-at-redeye-life-science-day-2022-in-swedish/2022-11-29T12:54:33+01:00https://www.activebiotech.com/en/presentation/active-biotech-ceo-helene-tuvesson-presents-at-redeye-fight-cancer-2023/2023-01-23T09:20:26+01:00https://www.activebiotech.com/en/presentation/infocus-interview-with-ceo-helen-tuvesson-at-redeye-growth-day-2023-june-1/2023-06-07T15:08:02+02:00https://www.activebiotech.com/en/presentation/active-biotech-presentation-at-aktiespararnas-aktiedag-lund-october-9-2023-in-swedish/2023-10-10T12:46:16+02:00https://www.activebiotech.com/en/presentation/redeye-video-interview-with-ceo-helen-tuvesson-in-swedish/2023-11-16T10:25:18+01:00https://www.activebiotech.com/en/presentation/active-biotech-ceo-helen-tuvesson-presents-at-redeye-life-science-day-2023-23-november/2023-11-27T10:59:27+01:00https://www.activebiotech.com/en/presentation/lead-principal-investigator-rebekka-schneider-kramann-presents-the-clinical-plan-and-positioning-of-tasquinimod-in-myelofibrosis-audiocast-summary/2023-12-01T09:32:54+01:00https://www.activebiotech.com/en/presentation/financialhearings-com-audiocast-the-clinical-plan-and-positioning-of-tasquinimod-in-myelofibrosis/2023-12-01T09:31:29+01:00https://www.activebiotech.com/en/presentation/ceo-helen-tuvesson-presents-at-investing-in-oncology-forum-april-10-2024/2024-04-10T14:44:03+02:00https://www.activebiotech.com/en/presentation/interview-with-prof-dr-axel-glasmacher-independent-board-member-at-active-biotech/2024-05-13T17:07:04+02:00https://www.activebiotech.com/en/presentation/infocus-interview-with-ceo-helen-tuvesson-at-redeye-growth-day-2023-may-30/2024-06-03T10:45:17+02:00https://www.activebiotech.com/en/presentation/redeye-video-interview-with-ceo-helen-tuvesson-in-swedish-2/2024-10-30T15:50:41+01:00https://www.activebiotech.com/en/presentation/infocus-interview-with-ceo-helen-tuvesson-at-redeye-technology-life-science-day-2024/2024-12-05T13:52:01+01:00https://www.activebiotech.com/en/presentation/interview-with-lucia-masarova-assistant-professor-at-md-anderson-cancer-center/2025-03-10T15:10:08+01:00https://www.activebiotech.com/en/presentation/redeye-interview-with-ceo-helen-tuvesson-and-cmo-erik-vahtola-in-swedish/2025-05-13T10:55:36+02:00https://www.activebiotech.com/en/presentation/safety-tolerability-and-distribution-of-topical-laquinimod-eye-drops-primary-outcomes-of-the-lion-study/2025-06-30T17:04:25+02:00https://www.activebiotech.com/en/presentation/redeye-active-biotech-presenation-and-interview-with-cmo-erik-vahtola-and-stanford-medicine-researchers/2025-06-30T17:08:55+02:00https://www.activebiotech.com/en/presentation/the-lion-study-safety-tolerability-and-distribution-of-topical-laquinimod-eye-drops-an-innovative-immunomodulator-targeting-aryl-hydrocarbon-receptor/2025-10-22T10:03:12+02:00https://www.activebiotech.com/en/presentation/redeye-active-biotech-intervju-redeye-pratar-med-vd-helen-tuvesson-om-nyemissionen-in-swedish/2025-10-24T14:45:27+02:00https://www.activebiotech.com/en/presentation/stora-aktiedagarna-stockholm-november-25-2025-in-swedish/2025-11-26T09:30:46+01:00https://www.activebiotech.com/en/presentation/redeye-active-biotech-intervju-redeye-pratar-med-vd-helen-tuvesson-om-nulaget-in-swedish/2026-07-03T10:15:10+02:00https://www.activebiotech.com/en/presentation/active-biotech-company-presentation/2026-07-03T10:17:45+02:00https://www.activebiotech.com/en/presentation/biostock-interview-with-helen-tuvesson-active-biotech-kommenterar-forsta-doseringen-i-uppdaterad-myelofibrosstudie-in-swedish/2026-08-17T12:04:57+02:00